Syngene International Reports Strong Financial Growth Amid Rising Costs in April 2025 Results

Syngene International, a prominent player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending March 2025. The results, declared on April 23, 2025, indicate a notable adjustment in evaluation, with the score rising significantly over the past three months.
The financial data reveals that Syngene International achieved a profit before tax (PBT) of Rs 221.60 crore, reflecting a substantial growth compared to the average of the previous four quarters. Similarly, the profit after tax (PAT) reached Rs 183.30 crore, also showing a marked increase over the prior averages. Net sales for the quarter hit a record high of Rs 1,018.00 crore, while operating profit (PBDIT) also reached its peak at Rs 343.60 crore in the last five quarters.

However, the company is facing challenges as well. Interest expenses have risen to Rs 15.90 crore, marking the highest level in five quarters, which indicates increased borrowings. Additionally, non-operating income has also reached a peak, raising concerns about its sustainability.

Overall, Syngene International's recent financial results reflect a complex landscape of growth and rising costs.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.